StockData
Coherus Oncology, Inc. logo

Coherus Oncology, Inc. (CHRS) stock

CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/3057% below fair value
$0.51−0.02 (-3.73%)

Close on Nov 16, 2026Market cap $78.16MP/E –Yield –

Coherus Oncology cash

Cash and short-term investments held at the end of each period.

Coherus Oncology's cash was $105.30M at Jun 30, 2026. For fiscal 2025 it was $172.13M, up 36.3% from the year before. Over ten years it grew 0.8% a year on average. The highest annual figure on record is $541.20M in fiscal 2020.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$172.13M+36.3%
FY2024Dec 31, 2024$126.25M+6.8%
FY2023Dec 31, 2023$118.20M-38.3%
FY2022Dec 31, 2022$191.68M-54.1%
FY2021Dec 31, 2021$417.20M-22.9%
FY2020Dec 31, 2020$541.20M+204.6%
FY2019Dec 31, 2019$177.67M+145.5%
FY2018Dec 31, 2018$72.36M-43.4%
FY2017Dec 31, 2017$127.76M+1.6%
FY2016Dec 31, 2016$125.79M-20.9%
FY2015Dec 31, 2015$159.07M+5.8%
FY2014Dec 31, 2014$150.39M+280.2%
FY2013Dec 31, 2013$39.55M+171.9%
FY2012Dec 31, 2012$14.55M+89.3%
FY2011Dec 31, 2011$7.68M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$105.30M-55.7%
Q1 FY2026Mar 31, 2026$167.05M+102.1%
Q4 FY2025Dec 31, 2025$172.13M+36.3%
Q3 FY2025Sep 30, 2025$191.66M+95.7%
Q2 FY2025Jun 30, 2025$237.90M+49.0%
Q1 FY2025Mar 31, 2025$82.67M-68.2%
Q4 FY2024Dec 31, 2024$126.25M+6.8%
Q3 FY2024Sep 30, 2024$97.95M-25.3%
Q2 FY2024Jun 30, 2024$159.69M+10.4%
Q1 FY2024Mar 31, 2024$260.23M+103.2%
Q4 FY2023Dec 31, 2023$118.20M-38.3%
Q3 FY2023Sep 30, 2023$131.08M-54.3%
Q2 FY2023Jun 30, 2023$144.71M-47.5%
Q1 FY2023Mar 31, 2023$128.09M-60.7%
Q4 FY2022Dec 31, 2022$191.68M-54.1%
Q3 FY2022Sep 30, 2022$286.81M-38.8%
Q2 FY2022Jun 30, 2022$275.48M-39.4%
Q1 FY2022Mar 31, 2022$325.68M-18.5%
Q4 FY2021Dec 31, 2021$417.20M-22.9%
Q3 FY2021Sep 30, 2021$468.71M-6.9%
Q2 FY2021Jun 30, 2021$454.42M-0.5%
Q1 FY2021Mar 31, 2021$399.50M+106.7%
Q4 FY2020Dec 31, 2020$541.20M+204.6%
Q3 FY2020Sep 30, 2020$503.43M+195.3%
Q2 FY2020Jun 30, 2020$456.50M+308.0%
Q1 FY2020Mar 31, 2020$193.30M+100.5%
Q4 FY2019Dec 31, 2019$177.67M+145.5%
Q3 FY2019Sep 30, 2019$170.50M+45.5%
Q2 FY2019Jun 30, 2019$111.90M-30.0%
Q1 FY2019Mar 31, 2019$96.40M+1.3%
Q4 FY2018Dec 31, 2018$72.36M-43.4%
Q3 FY2018Sep 30, 2018$117.20M-21.9%
Q2 FY2018Jun 30, 2018$159.80M+35.1%
Q1 FY2018Mar 31, 2018$95.20M-45.5%
Q4 FY2017Dec 31, 2017$127.76M+1.6%
Q3 FY2017Sep 30, 2017$150.10M-6.0%
Q2 FY2017Jun 30, 2017$118.30M–
Q1 FY2017Mar 31, 2017$174.80M–
Q4 FY2016Dec 31, 2016$125.79M–
Q3 FY2016Sep 30, 2016$159.68M–

More Coherus Oncology figures

See a number that looks wrong?